Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

3 Disease Trends Growing Molecular Diagnostics Beyond COVID-19, reports Kalorama Information


News provided by

Kalorama Information

Feb 15, 2023, 09:50 ET

Share this article

Share toX

Share this article

Share toX


Molecular diagnostics are useful in many disease areas and will continue to see sales. What are those areas? Kalorama information's market research provides the details.

ARLINGTON, Va., Feb. 15, 2023 /PRNewswire-PRWeb/ -- COVID-19 is not over, but test sales are clearly on the decline, and in vitro diagnostic (IVD) companies for the most part have adopted a focus on other test areas to beat the negative trend. Abbot, Roche, Hologic and Quest are among the diagnostic testing companies that have reported 2022 results with COVID-19 losses softened by gains in other tests areas. Their financials showed COVID-19 revenues sagged while other revenues grew. For instance Quest grew its base revenues 5% while COVID-19 testing dropped 48%, softening the blow. For Roche revenues were flat, with COVID-19 declines met almost equally by gains in chemistry and point of care (POC). This trend, of substituting COVID-19 for non-COVID-19 revenue in the market largely fits into predictions made by market research firm Kalorama Information in our reports, Worldwide Market for Molecular Diagnostics and Worldwide Market for In Vitro Diagnostics, 15th Edition.

Molecular diagnostics are useful in many disease areas and will continue to see sales. What are those areas? Kalorama's report The Worldwide Market for Molecular Diagnostics details some of these areas.

Growth in molecular diagnostics goes beyond COVID-19. - Kalorama Information

Post this

INFECTIOUS DISEASES: HIV, STI AND RESPIRATORY

HIV testing based on molecular methods is becoming a mature market segment. Yet HIV is still a problem in the world. The number of new HIV infections in the U.S. has been dropping — down from 41,200 in 2012 to 38,300 in 2017 — but fewer than half of adults in the U.S. have ever been tested for the virus. Most of the growth and innovation in the segment currently focus on antiviral therapy, which includes testing for viral load, viral tropism, and drug resistance. While the need for effective HIV screening and diagnosis is high in many developing markets, accessibility to such effective methods remains a challenge in most of these countries. Clinical approaches to HIV in the United States, Europe and other developed countries emphasize molecular testing as a tool for the management of chronic infection and achieving viral suppression. Recommendations released from the U.S. Preventive Services Task Force (USPSTF) continue to strongly advise HIV screening for adolescents and adults, and for the first time they support preventive treatment for those at high risk. The guidance could boost volume for blood tests.

The USPSTF, a volunteer group of independent experts that makes evidence-based assessments for disease prevention, published two recommendation statements on HIV screening and preventive treatment in the Journal of the American Medical Association (Vol. 321:22, pp. 2203-2213). The USPSTF's last guidance on this topic was published in 2013. The group gave an "A" recommendation to screening for HIV in adolescents and adults between the ages of 15 and 65 years and for all pregnant women. Furthermore, it advised screening for people younger than 15 and older than 65 who are at risk of getting infected. The USPSTF did not find enough evidence to set screening intervals, but it concluded that "repeat screening is reasonable for persons known to be at increased risk of HIV infection," including sexually active men who have sex with men, people who inject drugs, and/or those who are involved with commercial sex work.

In addition, Kalorama Information's report marks both STIs and non-COVID-19 respiratory as key growth areas.

INHERITED DISEASES – BIOMARKER IMPROVEMENT AND GROWING ACCEPTANCE OF TESTING

Alzheimer's disease (AD) is an aging-associated disease that manifests as dementia. The progression of the disease is associated with declines in memory and cognition, impaired judgment, and deterioration of personality. The disease afflicts over 5 million in the United States and is expected to reach 16 million by 2050.

Certain alleles of the apolipoprotein E (ApoE) gene are known as major risk markers for the development of AD. The advent of economical whole genome and exome sequencing in research has spurred investigation into weaker or secondary genetic loci for the disease. Whole genome sequencing of AD patients has identified several gene markers including CLU, CRI, PICALM, BIN1, and CNTN5.

The American Academy of Pediatrics and the American College of Medical Genetics recommend that all children diagnosed with autism be tested for Fragile X Syndrome and other chromosome abnormalities. These tests can help find genetic explanations in more than 10% of autism cases. Many more autism studies such as Kaiser Permanente's Autism Research Program are comprehensively testing patients diagnosed with autism as well as their families.

Cardiovascular disease, including heart attack and stroke, is the leading cause of death in the world and claims more lives than all forms of cancer combined. The number of deaths from cardiovascular disease (CVD) worldwide is projected to reach approximately 24 million by 2030. Approximately 80% of CVD-related deaths are in low- and middle-income countries. In developed countries such as the United States, CVD is one of the leading killers. Globally, CVD is on the rise as a result of sedentary lifestyle; changes in diet related to development (higher consumption of animal products); and smoking.

NAT BLOOD SCREENING – CONTINUE TO REPLACE IMMUNOASSAYS

In contrast, less growth will be seen in the nucleic acid test (NAT) Blood Screening category. Molecular blood screening tests, also known as Nucleic Acid Test blood screening tests, are trending. Though a fair amount of global blood screening is conducted by immunoassays, in major markets this category is growing.

Immunoassays are largely used to screen blood donations in developing nations as a routine approach. However, as a result of concerted efforts to make blood product transfusions safer, there is an increase in NAT screening to test for common pathogens. Developing countries are replacing immunoassays with molecular tests, especially for HIV, hepatitis, etc. Although infected donors can still test negative with NAT, the length of time between initial infection and a positive test result is shorter, resulting in fewer false negatives.

According to the World Health Organization (WHO), 13,000 blood centers in 176 countries collect whole blood, with about 79% of these units collected in high-income countries that have the resources to operate fully organized blood transfusion services and that screen donated blood for transfusion transmissible infections (TTIs), HIV, hepatitis B, hepatitis C, and syphilis. The WHO reports that almost all reporting countries screen donated blood for TTIs, but there are 13 countries that are not able to screen all donated blood for one or more of the above infections. Irregular supply of tests kits is the most common barrier to performing these tests.

The pioneers in the molecular diagnostics field include Roche Diagnostics, Gen-Probe, and Becton Dickinson. The main focus of the initial molecular diagnostics products was infectious disease including HIV, Chlamydia Trachomatis/Neisseria Gonorrhea (CT/NG), and TB. These diseases are still critical components of the market. Recently growth in molecular diagnostics methods has also been coming from inherited diseases, cancer, coagulation, and other areas.

ABOUT KALORAMA INFORMATION
Kalorama Information, part of Science and Medicine Group, is the leading publisher of market research in healthcare areas, including in vitro diagnostics (IVD), biotechnology, medical devices, and pharmaceuticals. Science and Medicine Group supports companies seeking to commercialize the rapidly changing marketplace at the intersection of science, medicine, and technology. Comprised of industry-leading brands, Science and Medicine Group serves analytical instrument, life science, imaging, and clinical diagnostic companies by helping them create strategies and products to win markets and provide platforms to digitally engage their markets through a variety of innovative solutions. Kalorama Information produces 30 reports a year. The firm offers a Knowledge Center, which provides access to all published reports.

Media Contact

DANIEL GRANDERSON, Kalorama Information, (703) 783-1721, [email protected]

SOURCE Kalorama Information

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.